Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by JohnBelgon Apr 16, 2019 1:04pm

105 Views

Post# 29634003

RE:RE:European Expansion News

FredTheVoice wrote:
Walshe said in this article: ONE YEAR ? What does that mean ?

FTV.

“The total lead time can be well over a year,” Walshe said."

Well over a year, not a year. I think it means revenues from Europe will take a long time to materialize. Clearly it has taken a long time in the States but maybe even slower in Europe. Many countries, more complexities. And we anticipate lower than USA prices. And a tougher deal with Taimed there than in the States as well.

John

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features